Compounded vs. Brand-Name GLP-1s — The Unbiased Breakdown

What compounded semaglutide and tirzepatide actually are, how 503A/503B pharmacies work, what changed after the shortages ended, and how to weigh cost against certainty.

What “compounded” actually means Compounding is pharmacy-made medication: a licensed pharmacy prepares a drug for an individual prescription rather than buying a factory-sealed product. It is a legal, regulated, and old practice — hormone creams, pediatric suspensions, and allergy-friendly reformulations have been compounded for decades. Two license types matter: - 503A pharmacies compound patient-specific prescriptions, regulated primarily by state boards of pharmacy. - 503B outsourcing facilities are FDA-registered, follow full manufacturing-grade quality standards (CGMP), and are inspected by FDA — generally the higher quality bar. ## The shortage era, and what changed During 2022–2024, semaglutide and tirzepatide were on FDA’s official shortage list, which temporarily allowed pharmacies to compound “essentially copies” of the brand drugs at scale. Both shortages have since been declared resolved, and the mass-copy era ended with them. Compounded GLP-1s did not disappear, though: pharmacies may still compound when a prescriber documents that a customized formulation serves the individual patient — a different strength or titration step than commercial pens offer, an added ingredient with clinical rationale (such as vitamin B6 for nausea), or a different dosage form (sublingual for needle aversion). That is the legal lane compounded GLP-1 programs operate in today, and it is also why legitimate programs document medical necessity rather than selling “cheap Wegovy.” ## The real trade-offs | | Brand (Wegovy/Zepbound) | Compounded | | --- | --- | --- | | FDA-approved product | Yes | No — pharmacy-prepared | | Clinical trial evidence | Directly tested in STEP/SURMOUNT | Inferred from the molecule; the specific formulation is untested | | Quality consistency | Factory-uniform | Depends on the pharmacy (503B > 503A on average) | | Typical cash cost | ≈$349–$549 (direct programs) | ≈$199–$450 | | Dose flexibility | Fixed pen/vial steps | Any prescribed increment — useful for slow titration and microdosing | | Forms | Injection (+ Rybelsus tablet) | Injection, sublingual RDT, B6 combinations | | Counterfeit risk | Low via legitimate pharmacies | Low via licensed pharmacies; high if you confuse compounding with gray-market vendors | ## How to think about the choice Choose brand if: insurance or direct-pharmacy pricing puts it within budget; you want the product with trial-proven, factory-consistent dosing; or you qualify for the cardiovascular indication where outcome data exists (semaglutide/SELECT). Compounded is reasonable if: you are cash-pay and the price gap is decisive; you need dose increments the pens do not offer (slow titration, maintenance microdosing); or you specifically want a needle-free sublingual form — provided you accept thinner evidence. Non-negotiables either way: a licensed prescriber who screens your history, a named licensed pharmacy (ask which one — good programs answer instantly), honest labeling of compounded products as compounded, and a human to call about side effects. Programs that fail any of these are not price bargains; they are risk transfers. The full vetting checklist is on where to get GLP-1s. ## Questions that expose a bad program in 60 seconds 1. “Which pharmacy fills this, and is it 503A or 503B?” (Stalling = walk away.) 2. “Is this FDA-approved?” (The only honest answer for compounded products is no — programs that dodge are lying about something.) 3. “Who reviews my labs or history before prescribing?” (A named clinician role, not ‘our system’.) 4. “What happens if I get bad nausea at week 3?” (There should be a protocol: dose hold, anti-nausea support, human contact.)